DEF: Arvinas Schedules 2026 Annual Meeting of Stockholders

Arvinas, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 24, 2026, to elect directors, vote on executive compensation, and ratify auditor appointment.

Summary

• Arvinas, Inc. is holding its 2026 Annual Meeting of Stockholders on June 24, 2026, at 8:00 a.m. Eastern Time.
• The meeting will be conducted exclusively as a virtual event via live audio webcast.
• Stockholders of record as of April 27, 2026, are eligible to vote.
• Key agenda items include the election of two Class II directors, a non-binding advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026.
• The company is providing proxy materials electronically via the internet, with a Notice of Internet Availability mailed around April 29, 2026.
• Stockholders can vote by proxy via the internet, telephone, or mail, or by voting online during the virtual meeting.
• The board of directors recommends voting FOR the director nominees, executive compensation approval, and auditor ratification.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and upcoming annual meeting matters. While it mentions past stock price declines and adjustments to compensation, the overall tone is procedural and forward-looking regarding the company's operations and pipeline.

Positives

• The company is facilitating greater stockholder participation by holding a virtual meeting, allowing attendance from any location.
• The board of directors is actively seeking stockholder input through advisory votes on executive compensation and by encouraging attendance and voting.
• The company is providing proxy materials electronically to reduce costs and environmental impact.
• The company has a robust corporate governance structure with independent directors and established board committees.
• The company has a clear process for director nominations and stockholder proposals.

Negatives

• One delinquent Section 16(a) filing was noted for Dr. Agarwal, filed one business day late.
• The company experienced a significant drop in share price following the VERITAC-2 Phase 3 clinical trial readout, which did not meet investor expectations, leading to proactive stockholder engagement and adjustments in compensation and cost structure.

Risks

• The filing references the Risk Factors section in the 2025 Annual Report for a comprehensive list of risks.
• The company's success is dependent on attracting, motivating, engaging, and retaining highly skilled employees.

Future Outlook

The company is progressing several product candidates through clinical development, including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS-mutated cancers, ARV-393 for non-Hodgkin lymphoma, ARV-027 for skeletal muscle targets, and vepdegestrant for breast cancer. The FDA has set a PDUFA action date of June 5, 2026, for vepdegestrant. The company anticipates its cash, cash equivalents, and marketable securities will fund operations into the second half of 2028.

Management Comments

• The board of directors recommends that you vote FOR each of the Class II director nominees (Proposal 1), and FOR each of Proposals 2 and 3.
• We believe that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world.
• Your vote is very important. Whether or not you plan to attend the Annual Meeting, we urge you to take the time to submit a proxy to vote your shares.

Industry Context

StockSavvy.ai notes that Arvinas's focus on PROTAC technology places it at the forefront of novel therapeutic modalities, aiming to address historically undruggable targets in oncology and neurology. The company's progress with vepdegestrant towards an FDA decision and the advancement of other pipeline candidates reflect the competitive landscape of the biopharmaceutical industry, where innovation and clinical success are paramount.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting agreement with John Houston, Ph.D., former President and CEO, for advisory services until March 1, 2027.
• Consulting agreement with Ian Taylor, Ph.D., former President of R&D, for advisory services for one year from his resignation date.
• EcoR1 Capital, LLC exercised its pre-funded warrants in March 2025, and subsequently reported no longer beneficially owning shares.
• Indemnification agreements are in place with all directors and executive officers.

Stakeholder Impact

• Shareholders: Voting rights on director elections, executive compensation, and auditor ratification; potential impact on share price from pipeline progress and FDA decisions.
• Employees: Continued focus on attracting, retaining, and developing talent through competitive compensation, benefits, and an inclusive work environment; potential impact from workforce reductions.
• Management: Executive compensation is tied to corporate performance and stockholder value, with adjustments made in response to stockholder feedback and market conditions.
• Auditors: Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026.

Next Steps

• Stockholders to vote on director elections, executive compensation, and auditor ratification at the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K within four business days.
• The FDA is expected to make a decision on the New Drug Application for vepdegestrant by June 5, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results or significant strategic shifts that would warrant a buy or sell recommendation. While the company's pipeline progress is a key factor, the information provided is primarily procedural. The past stock performance issues and compensation adjustments suggest a cautious approach is warranted, making 'hold' the most appropriate recommendation based solely on this document.

Keywords

Arvinas, Proxy Statement, Annual Meeting, Stockholders, Director Election, Executive Compensation, Independent Auditor, Corporate Governance, Virtual Meeting, SEC Filing